Category Archive for "Research"

Home »

A Strategic Look at CVS/TGT; Why We’re Still Bullish on RAD

CVS’ acquisition of TGT’s pharmacies raises from 17.6% to 22.7% the percent of the US population living in areas where CVS cannot be excluded from a retail pharmacy network (at least one that complies with commonly-used proximity standards). And, the

Read More

GOOG: A Particular Set of Skills

GOOG has levered its dominant prowess in data processing into market leadership in advertising, and plans to extend that leadership by orchestrating a mobile commerce ecosystem, with the potential to generate enormous value for itself and its partners. Investment in

Read More

ACA at the Supreme Court: Subsidies Are Here to Stay, Even if SCOTUS Finds for King

Congress cannot repeal the ACA; the President would almost certainly veto a repeal bill, and Republicans lack the two-thirds votes required in both chambers to overturn. (Republicans have 56 percent of House and 54 percent of Senate seats) And, Congress

Read More

US Drug Pricing Stalls. Uh-Oh …

Growth in US brand pharmaceuticals’ list prices has accelerated – but discounts are growing even faster. As a result, on average US brands’ net price growth is very nearly zero Net price growth is negative in 6 of the 10

Read More

TMT Model Portfolio Update: The Skeptics Guide

We assessed the valuations of 188 large cap TMT stocks, using our proprietary framework, which separates EV into near term and long term components. Graphed on these axes, the names fall into quadrants with interesting implications for trading. Historically, “Dream”

Read More

DuPont – A Slim Victory but Have Any Lessons Been Learned?

DuPont may have won the battle, albeit by a small margin, but in our view it is still very much in danger of losing the war.  Beating Trian in the recent proxy fight may be a cause for celebration in

Read More

SaaS Applications: [Subscription] Software is Eating the World!

SaaS enterprise applications make up a more than $31B market that is growing at more than 30%, and is projected to sustain 20% growth through 2018. SaaS products are a bundle, displacing not just the application, but also the enterprise

Read More

TMT: 1Q 2015 Earnings Rundown

Two main themes surprised us during 1Q15. First, advertisers are showing caution at a particularly eventful moment in the evolution of mobile commerce, and second, the enterprise transition to the cloud is playing out even faster and more profitably than

Read More

A WBA/RAD or CVS/RAD NEWCO as a Counterweight to Narrowing Retail Pharmacy Networks

This note updates our argument that US retail pharmacy networks are likely to narrow, compressing pharmacy dispensing margins – and in particular focuses on our belief that a WBA/RAD or CVS/RAD NEWCO is better able to withstand such margin pressures

Read More

SSR Health New Product Approval Portfolios & Supporting Data Update

Drug, biotech, and research-based spec pharma stocks tend to outperform their peers in the year or so before and after regulatory actions (‘PDUFA’ dates) on major new products, with a large portion of total risks being concentrated in the days

Read More
test